Sivelestat| CAS 127373-66-4

Cas No.:	127373-66-4
Chemical Name:	Sivelestat free acid
Synonyms:	(2-((4-(Pivaloyloxy)phenyl)sulfonamido)benzoyl)glycine;2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid;Sivelestat;EI 546;Elastase Inhibitor IV;LY544349;ONO5046;Sivelestat sodium salt hydrate;N-(2-(((4-(2,2-Dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)glycine;Sivelestate;Sivelestate sodium;Sivelestat (ONO-5046);Sivelestat sodium Impurity;EI 546 sodium salt hydrate;Elaspol sodium salt hydrate;ONO 5046;LY 544349;2-(2-(4-(pivaloyloxy)phenylsulfonamido)benzamido)acetic acid;ABT-D2E7;127373-66-4;BDBM166439;CHEMBL76688;SDCCGSBI-0633759.P001;2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester;SIVELESTAT [INN];BCP09708;2-[(2-{4-[(2,2-dimethylpropanoyl)oxy]benzenesulfonamido}phenyl)formamido]acetic acid;GTPL6441;SCHEMBL123221;NCGC00263570-02;DB12863;A857463;Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-;UNII-FYS6T7F842;o-(p-Hydroxybenzenesulfonamido)hippuric acid, pivalate (ester);NCGC00263570-03;N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid;CHEBI:135704;US9073833, Sivelestat;331731-18-1;N-[2-(N'-(Carboxymethyl)-aminocarbonyl)-phenyl]-4-t-butylcarbonyloxybenzenesulfonamide;Propanoic acid, 2,2-dimethyl-, 4-[[[2-[[(carboxymethyl)amino]carbonyl]phenyl]amino]sulfonyl]phenyl ester;Sivelestat [USAN];ONO5046;LY544349;EI546;D03788;UNII-DWI62G0P59;LY-544349;Ono-EI-600;SIVELESTAT [WHO-DD];BDBM50084637;AS-74843;HY-17443;Sivelestat (USAN/INN);EI546;J-005486;s8136;Q5646925;SIVELESTAT [MI];SIVELESTAT [MART.];EI546;LY544349;ONO5046;DWI62G0P59;DTXSID9048304;2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester(ONO-5046);AKOS022176173;MFCD00889071;Sivelestat [USAN:INN];NS00071648;CCG-269065;NCGC00346934-01;Ono-5046;Elastase Inhibitor IV - CAS 127373-66-4;BRD-K02152879-414-02-1;5134A;A11497;NCGC00263570-06;AT42741;BRD-K02152879-414-01-3;2-[[2-[[4-(2,2-Dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid;sivelestat
SMILES:	CC(C)(C)C(OC1=CC=C(S(=O)(NC2=CC=CC=C2C(NCC(O)=O)=O)=O)C=C1)=O
Formula:	C₂₀H₂₂N₂O₇S
M.Wt:	434.46
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM; also inhibits leukocyte elastase obtained from rabbit, rat, hamster and mouse, do not inhibit trypsin, thrombin, plasmin, plasma kallikrein, pancreas kallikrein, chymotrypsin and cathepsin G (>10 uM); attenuates LPS-induced acute lung inflammation in the hamster.Other IndicationApproved

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.